Omalizumab biosimilar - Glenmark Pharmaceuticals

Drug Profile

Omalizumab biosimilar - Glenmark Pharmaceuticals

Alternative Names: GBR 310

Latest Information Update: 05 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Allergic asthma; Urticaria

Most Recent Events

  • 25 Apr 2017 Clinical trials in Allergic asthma (In volunteers) in USA (Parenteral)
  • 25 Apr 2017 Clinical trials in Urticaria (In volunteers) in USA (Parenteral)
  • 25 Apr 2017 US FDA approves IND application for Omalizumab biosimilar in Allergic asthma and Urticaria (In volunteers)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top